SCHEMBL2997553

SCHEMBL2997553

CC(C)(C)OC(=O)N1CC(Oc2cnccn2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.52
GRIN1 Q05586 1/20 0.42
GRIN2B Q13224 1/20 0.42
CACNB4 O00305 1/20 0.42
CACNA1A O00555 1/20 0.42
CACNA1G O43497 1/20 0.42
CACNG3 O60359 1/20 0.42
CACNA1F O60840 1/20 0.42
CACNA1H O95180 1/20 0.42
CACNB3 P54284 1/20 0.42
CACNA2D1 P54289 1/20 0.42
CACNG7 P62955 1/20 0.42
CACNA1B Q00975 1/20 0.42
CACNA1D Q01668 1/20 0.42
CACNB1 Q02641 1/20 0.42
CACNG1 Q06432 1/20 0.42
CACNB2 Q08289 1/20 0.42
CACNA1S Q13698 1/20 0.42
CACNA1C Q13936 1/20 0.42
CACNA1E Q15878 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28664221 0.90 GPR119 (0.57) GPR119PIK3CDEPHX2PIK3CA
SCHEMBL28664219 0.90 GPR119 (0.57) GPR119PIK3CDEPHX2PIK3CA
SCHEMBL2775708 0.87 GPR119 (0.62) GPR119EPHX2CYP2C9NAAA
SCHEMBL30599901 0.82 GPR119 (0.52) GPR119CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL3001240 0.82 GPR119 (0.52) GPR119CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL12198294 0.81 GPR119 (0.50) GPR119CACNB4CACNA1ACACNA1GCACNG3
SCHEMBL1739261 0.80 EPHX2 (0.47) GRIN1GRIN2BEPHX2CYP2C9NAAA
SCHEMBL20989315 0.80 GPR119 (0.51) GPR119GRIN1GRIN2BEPHX2NAAA
SCHEMBL20989354 0.80 GPR119 (0.51) GPR119GRIN1GRIN2BEPHX2NAAA
SCHEMBL3505257 0.80 CACNB4 (0.45) GPR119CACNB4CACNA1ACACNA1GCACNG3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250215030-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. 2025-07-03 US disclosed
EP-4499656-A1 STAT MODULATORS AND USES THEREOF Recludix Pharma, Inc. (US) 2025-02-05 EP disclosed
US-20250026764-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 UNIV VANDERBILT (US) 2025-01-23 US disclosed
CN-119183453-A STAT modulators and uses thereof 瑞克鲁迪克斯制药股份有限公司 2024-12-24 CN disclosed
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-11-02 US disclosed
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-11-02 US disclosed
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 VANDERBILT UNIVERSITY 2023-11-02 US disclosed
WO-2023192960-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-10-05 WO disclosed
WO-2023192960-A1 STAT MODULATORS AND USES THEREOF RECLUDIX PHARMA, INC. (US) 2023-10-05 WO disclosed
EP-4186910-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 Vanderbilt University (US) 2023-05-31 EP disclosed
WO-2013053690-A1 PDE9I WITH IMIDAZO PYRAZINONE BACKBONE H. LUNDBECK A/S (DK) 2013-04-18 WO disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 US disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 US disclosed
US-20120329777-A1 Amino-Heterocyclic Compounds PFIZER INC. 2012-12-27 US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
US-8278295-B2 Amino-heterocyclic compounds PFIZER INC. (US) 2012-10-02 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PFIZER INC. 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348490-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM4, CHRM5, CHRM2 GPR119 220/4885GRIN1 101/4885GRIN2B 126/4885
US-20250215030-A1 STAT MODULATORS AND USES THEREOF STAT6, STAT3, STAT5A GPR119 386/4885GRIN1 4221/4885GRIN2B 4227/4885
US-20250026764-A1 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 CHRM4, CHRM5, CHRM2 GPR119 220/4885GRIN1 101/4885GRIN2B 126/4885
US-20120329777-A1 Amino-Heterocyclic Compounds PDE9A, PDE2A, PDE10A GPR119 95/4885GRIN1 356/4885GRIN2B 406/4885
US-20100190771-A1 AMINO-HETEROCYCLIC COMPOUNDS PDE9A, PDE2A, PDE10A GPR119 95/4885GRIN1 356/4885GRIN2B 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.